Efficacy of Neoadjuvant Targeted Therapy for Borderline Resectable III B-D or IV Stage BRAF (V600) Mutation-Positive Melanoma

SIMPLE SUMMARY: Neoadjuvant therapy for locally advanced disease or potentially resectable metastatic melanoma is expected to improve operability and clinical outcomes over upfront surgery. 46 patients were treated with BRAFi/MEKi or BRAFi before surgery with 78% R0 resection. In patients with a maj...

Descripción completa

Detalles Bibliográficos
Autores principales: Czarnecka, Anna M., Ostaszewski, Krzysztof, Borkowska, Aneta, Szumera-Ciećkiewicz, Anna, Kozak, Katarzyna, Świtaj, Tomasz, Rogala, Paweł, Kalinowska, Iwona, Koseła-Paterczyk, Hanna, Zaborowski, Konrad, Teterycz, Paweł, Tysarowski, Andrzej, Makuła, Donata, Rutkowski, Piotr
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8744603/
https://www.ncbi.nlm.nih.gov/pubmed/35008274
http://dx.doi.org/10.3390/cancers14010110

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8744603/
https://www.ncbi.nlm.nih.gov/pubmed/35008274
http://dx.doi.org/10.3390/cancers14010110

Ejemplares similares